FUNCTIONAL STATE OF NEUTROPHIC GRANULOCYTES’ GENOME OF THE PERIPHERAL BLOOD IN PATIENTS WITH CHRONIC HEPATITIS C WITH CONCOMITANT DIABETES MELLITUS TYPE II-Reference-Cited by-同舟云学术

FUNCTIONAL STATE OF NEUTROPHIC GRANULOCYTES’ GENOME OF THE PERIPHERAL BLOOD IN PATIENTS WITH CHRONIC HEPATITIS C WITH CONCOMITANT DIABETES MELLITUS TYPE II

Published:2020 Issue:8 Volume:73 Page:1671-1676
ISSN:0043-5147
Container-title:Wiadomości Lekarskie
language:en
Short-container-title:Wiad Lek

Author:

Pryshliak Oleksandra Ya.¹,Kovalchuk Larysa Ye.¹,Marynchak Oleksandra V.¹,Boichuk Oleksandr P.¹,Hryzhak Ihor H.¹,Kondryn Oksana Ye.¹,Piuryk Valentyna F.¹

Affiliation:

1. IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE

Abstract

The aim: To determine changes of FSG of neutrophilic granulocytes of peripheral blood (NGPB) of patients with CHC with concomitant DM-2. Materials and methods: We’ve examined 180 patients with CHC: 160 with concomitant diabetes mellitus and 20 ones without it. The NGPB genome was studied using cytogenetic method. There were analyzed 100 interphase NGPB nuclei in the preparation, structural characteristics were evaluated according to indices: chromatization (IC), nucleolar (IN), pathologically altered nuclei (PAN), micronuclei (MNI). Results: Violations of FSG OF NGPBwere found according to all indices in patients with CHC, they were more pronounced in patients with concomitant DM-2. Conclusions: FSG NGPB is more disordered in CHC with concomitant DM-2. The reduction of IC in CHC with concomitant DM-2 is more pronounced in men. Reduction of IN in patients with CHC with and without DM-2 is a marker of violations of the second stage of realization of hereditary information. The tendency to change the components of the cytogenetic status of all examined patients due to the frequency of MNI was determined.

Publisher

ALUNA

Subject

General Medicine

Reference29 articles.

1. 1. Hanafiah K.M., Groeger J., Flaxman A.D. et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57:1333–1342.

2. 2. Popping S., El-Sayed M., Feld J., Hatzakis A., et al. Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17–18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework. J Virus Erad. 2018; 4 (3): 193-195.

3. 3. Giada S., Gkouvatsos K., Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014; 20(32):11033–11053.

4. 4. Saeedi P., Petersohn I., Salpea P., Malanda B. et al. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 204 5: Results From the International Diabetes Federation Diabetes Atlas, 9 th Edition, Diabetes Res Clin Pract. 2019; (9):10 DOI: 10.1016/j. diabres.2019.107843.

5. 5. Zheng Y., Ley S.H., Hu F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98.